SPRC

SciSparc Ltd. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website cisparc.com
Employees(FY) 3
ISIN IL0010951403

Performance

+0.59%

+3.88%

-43.31%

-80.48%

-95.12%

YTD

-96.17%

Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and epilepsy and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation, as well as a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. The company was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Advanced Technical Analysis

Technical Analysis of SPRC 2024-11-20

The stock's indicators reflect a neutral sentiment, with the Moving Average Score at 50, Oscillators Score at 53, and a Technical Score of 51, suggesting a balanced market condition without strong bullish or bearish momentum. Overall, these scores indicate that the stock is currently in a consolidation phase, warranting cautious observation for ...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SPRC

Stock Rank

Recent News & Updates

2024-09-30 18:33
SciSparc receives FDA approval for trial for Tourette syndrome therapy(Yahoo Finance)
2024-09-29 21:25
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment(Globenewswire)
2024-09-25 21:05
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX(Globenewswire)
2024-09-22 20:17
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment(Globenewswire)
2024-09-18 04:09
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment(Globenewswire)
2024-09-16 04:06
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy(Globenewswire)
2024-09-16 04:06
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy(Globenewswire)
2024-09-10 19:40
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer(Globenewswire)
2024-09-05 19:55
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment(Globenewswire)
2024-09-05 19:55
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment(Globenewswire)
2024-08-29 04:25
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination(Globenewswire)
2024-08-29 04:25
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment(Globenewswire)
2024-08-27 20:55
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million(Globenewswire)
2024-08-25 16:52
SciSparc secures final approval in Israel to start Tourettes Syndrome trial(Yahoo Finance)
2024-08-25 16:32
SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial(Yahoo Finance)
2024-08-23 04:09
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome(Globenewswire)
2024-08-21 20:12
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board(Globenewswire)
2024-08-19 04:11
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment(Globenewswire)
2024-08-18 18:33
SciSparc and Polyrizon sign global agreement for pain therapy(Yahoo Finance)
2024-08-16 04:30
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million(Globenewswire)
2024-08-14 04:53
SciSparc Updates Regarding the Status of the AutoMax Merger(Globenewswire)
2024-08-05 20:57
SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug(Globenewswire)
2024-07-21 20:20
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer(Globenewswire)
2024-07-16 19:07
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million(Globenewswire)
2024-07-15 23:55
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification(Globenewswire)
2024-07-15 23:01
Mizuho Just Issued a Warning on Palantir (PLTR) Stock(Investorplace)
2024-07-15 22:43
Why Is SciSparc (SPRC) Stock Up 25% Today?(Investorplace)
2024-07-15 19:43
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday(Investorplace)
2024-07-15 18:03
Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss(Globenewswire)
2024-07-15 18:03
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.